

We are the only PARKINSON'S FOUNDATION CENTER OF EXCELLENCE in the region with comprehensive care including doctors specialized in the diagnostics, treatment, research, and education of Parkinson's disease. We have a large multi-disciplinary team including healthcare professionals specialized in Parkinson's disease in the areas of psychology, speech, physical therapy, occupational therapy, dietetics, social work, pharmacy, neuropsychology, and neurosurgery, including a large deep brain stimulation program.

16th Annual Parkinson's Disease Symposium, Saturday August 24, 2024!

We are excited to announce that our Parkinson's Disease Symposium will be at the Overland Park Marriott on August 24, 2024! Doors open at 8:00am for exhibits, and presentations will begin at 9:00am. The presentations include: **Diagnosing PD and Related Disorders**, Dr. Kelvin Au; **Current and Upcoming Treatment Options for PD**, Dr. Angela Richmond; **Shades of Lewy Body Disease: Exploring the Spectrum Between Parkinson's and Dementia**, Dr. Ryan Townley; **Fitness Counts: Physical Therapy, Exercise, and Parkinson's Disease**, Maria Davenport; **Sleep and PD**, Dr. Jennifer Liebenenthal; **Questions & Answers**, Dr. Rajesh Pahwa & Dr. Stuart Isaacson. The program is free but registration is requested. Light snacks, coffee, and water will be provided. Parking is free outside the Overland Park Marriott. To register email pdetcenter@kumc.edu or call 913-588-0013 or

CLICK HERE TO REGISTER FOR SYMPOSIUM



RAJESH PAHWA, MD

Laverne & Joyce Rider
Professor of Neurology

Director, Parkinson's
Disease and Movement
Disorder Center



KELLY LYONS, PhD

Research Professor
of Neurology

Director, Research and
Education, Parkinson's Disease
and Movement Disorder Center

TREMOR CORNER

ET Studies Ongoing!

Felix— Wrist-worn neurostimulation device with AI technology to control moderate to severe ET interfering with daily tasks like writing, eating drinking, etc. throughout the day.

ATTN201 - Headband device providing noninvasive focused ultrasound with no surgery required. Study for persons with moderate to severe ET interfering with daily activities.

To participate in a research study or for more information, email pdetcenter@kumc.edu or call 913-588-7159

The International Essential Tremor Foundation (IETF) provides education, support and resources for ET. Visit www.essentialtremor.org for upcoming programs and more information.

PARKINSON'S STUDIES CURRENTLY RECRUITING

- Newly diagnosed - Possible disease slowing LUMA** - diagnosed < 2 years, not taking PD medications
- Early PD - Control of Symptoms CVN424** - not taking PD medications, symptoms < 4 years
- STEM-PD** - Headphone-like device for non-motor symptoms like thinking, memory, dizziness, fatigue, depression, anxiety, etc.
- PD patients experiencing OFF time (poor symptom control) ITI** - at least 2.5 hrs OFF time daily and some dyskinesia
UCB PD0060 - >2hrs OFF time
- SHARPEN** - Home use neurostimulation for the treatment of Parkinson's disease dementia (issues with memory/thinking)
- ASK Bio** - Glial cell-line derived neurotrophic factor (GDNF) - surgical procedure to increase survival of dopamine neurons
- Persons with multiple system atrophy (MSA)**
- Persons with progressive supranuclear palsy (PSP)**
- PD Generation: Mapping the Future of Parkinson's Disease**
Testing for 7 genes that may increase PD risk.
Anyone with PD can participate in person or virtually
- The Parkinson's Progression Markers Initiative (PPMI)**
--- Prodrional cohort (1st degree relative with PD, REM sleep behavior disorder (RBD), or known genetic variants; age 60+
--- Healthy Controls (30+ years of age)
- TOPAZ** - Home study to prevent fractures in people with PD

NEW RESEARCH STUDY FOR PD

Glial Cell-Line Derived Neurotrophic Factor (GDNF)

GDNF is a protein that naturally occurs in the brain. It promotes the survival of different brain cells including dopamine which is depleted in persons with PD. In a small study, this treatment was found to be safe and well-tolerated. A larger study is now underway.

In the **ASK Bio REGENERATE-PD Study**, GDNF will be used in an attempt to increase the survival of dopamine neurons and reduce the symptoms of PD.

The study is for persons with moderate PD:

- Persons with an age between 45 and 75 years
- Diagnosed with PD in the last 4-10 years
- At least 2.5 hours of OFF time daily (periods during the waking hours when PD symptoms are not well controlled by medications)
- Stable PD medications for at least 4 weeks
- Daily levodopa dose of at least 300 mg
- Good response to levodopa (significant difference in symptoms when ON and OFF levodopa)
- Cannot have an atypical form of PD (although other studies available for those with atypical parkinsonism, MSA and PSP)
- No previous surgery for PD including deep brain stimulation (DBS), focused ultrasound (FUS) or infusion therapies.

If you are interested in learning more about this study please email PDETCenter@kumc.edu or call 913-588-7159

Visit our website: KUMC.EDU/PARKINSON for more information on PD and ET

For information about any research studies, please email PDETCenter@kumc.edu or call 913-588-7159.